Hamilton Lane Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Hamilton Lane Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-1,031	Closed	–	–	51
2018 Q1	$0	Hold	1,031	–	–	﹤0.01%	55
2017 Q4	$100K	Sell	1,031 -1,000	-49%	-$134K	0.05%	54
2017 Q3	$299K	Buy	+2,031	New	+$382K	0.21%	46
2016 Q4	–	Sell	-1,388	Closed	-$193K	–	69
2016 Q3	$193K	Buy	+1,388	New	+$176K	0.1%	58

Other funds holding SYRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hamilton Lane Advisors's SYRS Position: Q2 2018 in Review

Hamilton Lane Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2018, closing a stake of 1,031 shares.

Hamilton Lane Advisors first reported a position in SYRS in Q3 2016 and held it in 4 quarters. The position peaked at $299K in Q3 2017. 76 funds tracked by Wall St. Rank hold SYRS as of Q2 2018.

Hamilton Lane Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
Hamilton Lane Advisors sold 1,031 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2018.
Hamilton Lane Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2016 and held it in 4 quarters.
Hamilton Lane Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $299K in Q3 2017.
76 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2018.

Based on Hamilton Lane Advisors's 13F filing for Q2 2018, filed 31 Jul 2018.